FORMULARY FATE OF PIPELINE DRUGS FOR NON-SMALL CELL LUNG CANCER: A COMPARATIVE STUDY OF TARGETED THERAPIES OBJECTIVE: The incidence of Non-Small Cell Lung Cancer (NSCLC) is high; therefore commercial opportunity exists for developers that are able to penetrate the NSCLC therapy market. The emerging therapies for NSCLC are one of the most congested and targeted oncology indication, majority of agents are in phase II/III clinical development. To evaluate pipeline drugs and focus on its improving outcomes, which will provide benefit to largest drug treatable population in NSCLC, a research is being conducted to demonstrate which class of drug will provide best result to improve the patient condition suffering from NSCLC. METHOD: To draw insight for research, data covered from clinicaltrail.gov (NSCLC pipeline agents at various stages of development), compared therapeutic assessments by molecule type, monotherapy and combination products, route of administration, publically available CMS data, company’s websites, investor presentations, and SEC filings and featured press releases from companies and also including news to track the most recent updates. RESULT: PD-1 Inhibitors (Immune checkpoint inhibitors), epidermal growth factor receptor (EGFR) antagonists –tyrosine kinase inhibitors (TKIs) and anaplastic lymphoma kinase (ALK) inhibitors classes of pipeline drugs are studied and analyzed.  PD-1 inhibitors and EGFR-inhibitors drugs showed positive clinical outcomes and have probability to cover by major formularies. CONUSION: Drugs that succeed in providing even incremental survival benefits could be very successful commercially in NSCLC indication. The market for EGFR inhibitors will be more lucrative followed by PD-1 inhibitors. After, the expected launch of drugs that are in pipeline will provide better option for oncologist to suggest best therapies for patients suffering from NSCLC. Further, by demonstrating positive clinical outcomes and cost effectiveness of pipeline drugs, faster formulary placement of molecules can be attained.